A Masked, Placebo-controlled Study to Assess Iptacopan in Age-related Macular Degeneration

To join this study, you need to be at least 50 years old. You must have a diagnosis of early or intermediate AMD in one eye, along with specific features visible on eye scans. In your other eye, you must have a diagnosis of a more advanced type of AMD called neovascular AMD.

Before starting the study medicine, you'll need to have certain vaccinations to protect against infections like meningitis and pneumonia. If available and suitable, you should also be vaccinated against Haemophilus influenzae.

There are several reasons why you might not be able to join. These include certain heart conditions, a history of stroke or heart attack in the past six months, kidney failure requiring dialysis or transplant, cancer, organ transplants, or recurrent meningitis. You also can't participate if you have certain infections like HIV, Hepatitis B or C, or if you're allergic to any of the study medicines or similar substances.

If you decide to take part, you'll first have a screening visit to check if you meet all the study requirements. If you're eligible, you'll be randomly assigned to receive either the study medicine, Iptacopan, or a placebo (a dummy pill). Both are taken as oral capsules.

You'll be asked to attend several follow-up visits with the study team. These visits will involve various tests and examinations to check your eye health, general health, and how you are responding to the treatment. They'll also monitor for any side effects. The total length of your participation in the study, including the follow-up, will be determined by the study design, and your study team will give you all the details.

Throughout the study, you'll be closely monitored by medical professionals. It's important to attend all scheduled appointments and report any new symptoms or concerns to the study staff.